Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Determination of unbound vismodegib (GDC-0449) concentration in human plasma using rapid equilibrium dialysis followed by solid phase extraction and high-performance liquid chromatography coupled to mass spectrometry.
Deng Y, Wong H, Graham RA, Liu W, Shen HS, Shi Y, Wang L, Meng M, Malhi V, Ding X, Dean B. Deng Y, et al. Among authors: malhi v. J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Jul 15;879(22):2119-26. doi: 10.1016/j.jchromb.2011.05.048. Epub 2011 Jun 12. J Chromatogr B Analyt Technol Biomed Life Sci. 2011. PMID: 21704573
Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential.
LoRusso PM, Piha-Paul SA, Mita M, Colevas AD, Malhi V, Colburn D, Yin M, Low JA, Graham RA. LoRusso PM, et al. Among authors: malhi v. Cancer Chemother Pharmacol. 2013 Jan;71(1):193-202. doi: 10.1007/s00280-012-1996-6. Epub 2012 Oct 11. Cancer Chemother Pharmacol. 2013. PMID: 23064958 Clinical Trial.
A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib.
Malhi V, Colburn D, Williams SJ, Hop CE, Dresser MJ, Chandra P, Graham RA. Malhi V, et al. Cancer Chemother Pharmacol. 2016 Jul;78(1):41-9. doi: 10.1007/s00280-016-3020-z. Epub 2016 May 6. Cancer Chemother Pharmacol. 2016. PMID: 27154174 Free PMC article. Clinical Trial.
A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.
Couban S, Benevolo G, Donnellan W, Cultrera J, Koschmieder S, Verstovsek S, Hooper G, Hertig C, Tandon M, Dimier N, Malhi V, Passamonti F. Couban S, et al. Among authors: malhi v. J Hematol Oncol. 2018 Sep 24;11(1):122. doi: 10.1186/s13045-018-0661-x. J Hematol Oncol. 2018. PMID: 30249277 Free PMC article. Clinical Trial.
The Absolute Bioavailability and Absorption, Metabolism, and Excretion of Ipatasertib, a Potent and Highly Selective Protein Kinase B (Akt) Inhibitor.
Takahashi RH, Malhi V, Liederer BM, Cho S, Deng Y, Dean B, Nugteren J, Yost E, Al-Sayah MA, Sane R, Kshirsagar S, Ma S, Musib L. Takahashi RH, et al. Among authors: malhi v. Drug Metab Dispos. 2023 Oct;51(10):1332-1341. doi: 10.1124/dmd.122.001175. Epub 2023 Jul 31. Drug Metab Dispos. 2023. PMID: 37524543
18 results